PubRank

Giorgio Parmiani

Author PubWeight™ 123.51‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci U S A 2007 13.58
2 Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J Clin Oncol 2007 6.68
3 Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group. J Clin Oncol 2008 3.82
4 Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles. J Exp Med 2002 3.02
5 Interleukin-12: biological properties and clinical application. Clin Cancer Res 2007 3.00
6 A clinical development paradigm for cancer vaccines and related biologics. J Immunother 2007 2.97
7 Tumor-released microvesicles as vehicles of immunosuppression. Cancer Res 2007 2.80
8 Cannibalism of live lymphocytes by human metastatic but not primary melanoma cells. Cancer Res 2006 2.77
9 Human tumor-released microvesicles promote the differentiation of myeloid cells with transforming growth factor-beta-mediated suppressive activity on T lymphocytes. Cancer Res 2006 2.61
10 Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. J Clin Oncol 2002 2.57
11 Defining the critical hurdles in cancer immunotherapy. J Transl Med 2011 2.32
12 A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol Immunother 2004 2.16
13 Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. Lancet Oncol 2012 2.03
14 Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs. J Natl Cancer Inst 2004 2.02
15 Human colorectal cancer cells induce T-cell death through release of proapoptotic microvesicles: role in immune escape. Gastroenterology 2005 2.00
16 Immunity to cancer: attack and escape in T lymphocyte-tumor cell interaction. Immunol Rev 2002 1.66
17 Immunology and immunotherapy of colorectal cancer. Crit Rev Oncol Hematol 2003 1.61
18 Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma. Cancer Res 2003 1.60
19 BRAF alterations are associated with complex mutational profiles in malignant melanoma. Oncogene 2004 1.58
20 NKG2D-mediated antitumor activity by tumor-infiltrating lymphocytes and antigen-specific T-cell clones isolated from melanoma patients. Clin Cancer Res 2007 1.50
21 Cutaneous melanoma in childhood and adolescence shows frequent loss of INK4A and gain of KIT. J Invest Dermatol 2009 1.48
22 Vaccination with autologous tumor-derived heat-shock protein gp96 after liver resection for metastatic colorectal cancer. Clin Cancer Res 2003 1.46
23 Clinical and immunologic responses in melanoma patients vaccinated with MAGE-A3-genetically modified lymphocytes. Int J Cancer 2012 1.45
24 Modulation of microenvironment acidity reverses anergy in human and murine tumor-infiltrating T lymphocytes. Cancer Res 2012 1.41
25 LAG-3 expression defines a subset of CD4(+)CD25(high)Foxp3(+) regulatory T cells that are expanded at tumor sites. J Immunol 2010 1.37
26 Immunobiological characterization of cancer stem cells isolated from glioblastoma patients. Clin Cancer Res 2010 1.37
27 Heterogeneous phenotype of human melanoma cells with in vitro and in vivo features of tumor-initiating cells. J Invest Dermatol 2010 1.35
28 Reconstitution of human telomerase reverse transcriptase expression rescues colorectal carcinoma cells from in vitro senescence: evidence against immortality as a constitutive trait of tumor cells. Cancer Res 2005 1.24
29 Heat shock proteins: biological functions and clinical application as personalized vaccines for human cancer. Cancer Immunol Immunother 2003 1.20
30 Targeting TNF-α to neoangiogenic vessels enhances lymphocyte infiltration in tumors and increases the therapeutic potential of immunotherapy. J Immunol 2012 1.17
31 Potent phagocytic activity discriminates metastatic and primary human malignant melanomas: a key role of ezrin. Lab Invest 2003 1.17
32 Naturally occurring peptides associated with HLA-A2 in ovarian cancer cell lines identified by mass spectrometry are targets of HLA-A2-restricted cytotoxic T cells. Int Immunol 2003 1.17
33 A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-alpha in metastatic melanoma patients. Cancer Immunol Immunother 2005 1.17
34 Limited induction of tumor cross-reactive T cells without a measurable clinical benefit in early melanoma patients vaccinated with human leukocyte antigen class I-modified peptides. Clin Cancer Res 2012 1.15
35 CCN3/nephroblastoma overexpressed matricellular protein regulates integrin expression, adhesion, and dissemination in melanoma. Cancer Res 2008 1.14
36 Human NK cells selective targeting of colon cancer-initiating cells: a role for natural cytotoxicity receptors and MHC class I molecules. J Immunol 2013 1.11
37 The apoptosis inhibitor protein survivin induces tumor-specific CD8+ and CD4+ T cells in colorectal cancer patients. Cancer Res 2003 1.06
38 Detection of mutated BRAFV600E variant in circulating DNA of stage III-IV melanoma patients. Int J Cancer 2007 1.06
39 Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors. Cancer Res 2006 1.06
40 Human tumor-derived heat shock protein 96 mediates in vitro activation and in vivo expansion of melanoma- and colon carcinoma-specific T cells. J Immunol 2003 1.06
41 Escape strategies and reasons for failure in the interaction between tumour cells and the immune system: how can we tilt the balance towards immune-mediated cancer control? Expert Opin Biol Ther 2005 1.02
42 Role of cross-talk between IFN-alpha-induced monocyte-derived dendritic cells and NK cells in priming CD8+ T cell responses against human tumor antigens. J Immunol 2004 1.01
43 Non-redundant role for IL-12 and IL-27 in modulating Th2 polarization of carcinoembryonic antigen specific CD4 T cells from pancreatic cancer patients. PLoS One 2009 1.00
44 PTPRK negatively regulates transcriptional activity of wild type and mutated oncogenic beta-catenin and affects membrane distribution of beta-catenin/E-cadherin complexes in cancer cells. Cell Signal 2008 0.96
45 TNK cells (NKG2D+ CD8+ or CD4+ T lymphocytes) in the control of human tumors. Cancer Immunol Immunother 2008 0.96
46 Soluble human LAG-3 molecule amplifies the in vitro generation of type 1 tumor-specific immunity. Cancer Res 2006 0.95
47 Boosting T cell-mediated immunity to tyrosinase by vaccinia virus-transduced, CD34(+)-derived dendritic cell vaccination: a phase I trial in metastatic melanoma. Clin Cancer Res 2004 0.95
48 Antigen-specific immunity in neuroblastoma patients: antibody and T-cell recognition of NY-ESO-1 tumor antigen. Cancer Res 2003 0.93
49 Human plasmacytoid dendritic cells interact with gp96 via CD91 and regulate inflammatory responses. J Immunol 2008 0.92
50 Effect of human natural killer and gammadelta T cells on the growth of human autologous melanoma xenografts in SCID mice. Cancer Res 2004 0.90
51 Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme. J Exp Clin Cancer Res 2014 0.89
52 Differentiation of CD8+ T cells from tumor-invaded and tumor-free lymph nodes of melanoma patients: role of common gamma-chain cytokines. J Immunol 2003 0.88
53 Modified peptides in anti-cancer vaccines: are we eventually improving anti-tumour immunity? Cancer Immunol Immunother 2008 0.87
54 Somatically mutated tumor antigens in the quest for a more efficacious patient-oriented immunotherapy of cancer. Cancer Immunol Immunother 2014 0.86
55 Adoptive transfer of an anti-MART-1(27-35)-specific CD8+ T cell clone leads to immunoselection of human melanoma antigen-loss variants in SCID mice. Eur J Immunol 2003 0.86
56 Cancer-initiating cells from colorectal cancer patients escape from T cell-mediated immunosurveillance in vitro through membrane-bound IL-4. J Immunol 2013 0.86
57 Immunogenicity without immunoselection: a mutant but functional antioxidant enzyme retained in a human metastatic melanoma and targeted by CD8(+) T cells with a memory phenotype. Cancer Res 2005 0.86
58 Vaccination therapy in prostate cancer. Cancer Immunol Immunother 2006 0.85
59 NKG2D engagement of colorectal cancer-specific T cells strengthens TCR-mediated antigen stimulation and elicits TCR independent anti-tumor activity. Eur J Immunol 2003 0.85
60 Low TCR avidity and lack of tumor cell recognition in CD8(+) T cells primed with the CEA-analogue CAP1-6D peptide. Cancer Immunol Immunother 2007 0.85
61 Identification of a mutated receptor-like protein tyrosine phosphatase kappa as a novel, class II HLA-restricted melanoma antigen. J Immunol 2003 0.84
62 Natural killer and NK-Like T-cell activation in colorectal carcinoma patients treated with autologous tumor-derived heat shock protein 96. Cancer Res 2005 0.84
63 Vaccination of stage IV patients with allogeneic IL-4- or IL-2-gene-transduced melanoma cells generates functional antibodies against vaccinating and autologous melanoma cells. Cancer Immunol Immunother 2001 0.84
64 Human lymphocyte activation gene-3 molecules expressed by activated T cells deliver costimulation signal for dendritic cell activation. J Immunol 2008 0.83
65 Effects of cyclophosphamide and IL-2 on regulatory CD4+ T cell frequency and function in melanoma patients vaccinated with HLA-class I peptides: impact on the antigen-specific T cell response. Cancer Immunol Immunother 2013 0.82
66 Pre-clinical and clinical aspects of peptide-based vaccine against human solid tumors. Recent Pat Biotechnol 2011 0.82
67 Follow-up of melanoma: a survey of Italian hospitals. Dermatology 2013 0.82
68 Surgical treatment of melanoma: a survey of Italian hospitals. Dermatology 2013 0.82
69 Suboptimal activation of CD8(+) T cells by melanoma-derived altered peptide ligands: role of Melan-A/MART-1 optimized analogues. Cancer Res 2003 0.82
70 Immunomodulation in a treatment program including pre- and post-operative interleukin-2 and chemotherapy for childhood osteosarcoma. Tumori 2003 0.81
71 T cell infiltration and prognosis in HCC patients. J Hepatol 2006 0.80
72 Clinical protocol. Immunization of patients with malignant melanoma with autologous CD34(+) cell-derived dendritic cells transduced ex vivo with a recombinant replication-deficient vaccinia vector encoding the human tyrosinase gene: a phase I trial. Hum Gene Ther 2003 0.79
73 Induction of both CD8+ and CD4+ T-cell-mediated responses in colorectal cancer patients by colon antigen-1. Clin Cancer Res 2008 0.79
74 Type I interferon gene transfer sensitizes melanoma cells to apoptosis via a target activity on mitochondrial function. Am J Pathol 2002 0.79
75 International meeting on cancer vaccines: how can we enhance efficacy of therapeutic vaccines? Cancer Res 2004 0.79
76 Chemokine receptor 7, a new player in regulating apoptosis of CD8+ T cells in cancer patients. Clin Cancer Res 2005 0.79
77 A merging duo in melanoma formation. J Invest Dermatol 2005 0.79
78 Vaccination: role in metastatic melanoma. Expert Rev Anticancer Ther 2006 0.77
79 What is new in melanoma research? Vaccines, Basic and Translational Research in 2003: report of a workshop at the Third Research Meeting on Melanoma, Milan, Italy, May 2003. Melanoma Res 2004 0.77
80 Ex vivo enrichment of circulating anti-tumor T cells from both cutaneous and ocular melanoma patients: clinical implications for adoptive cell transfer therapy. Cancer Immunol Immunother 2011 0.77
81 Awareness and understanding of cancer immunotherapy in Europe. Hum Vaccin Immunother 2014 0.77
82 Comparative assessment of TCRBV diversity in T lymphocytes present in blood, metastatic lesions, and DTH sites of two melanoma patients vaccinated with an IL-7 gene-modified autologous tumor cell vaccine. Cancer Gene Ther 2002 0.77
83 International meeting "Immunotherapy of cancer: challenges and needs". Cancer Immunol Immunother 2006 0.76
84 Limitations of the cancer stem cell theory. Cytotechnology 2008 0.76
85 When transgenes shape immunity: cancer immune-gene therapy. J Gene Med 2012 0.75
86 The Italian Network for Tumor Biotherapy (NIBIT): getting together to push the field forward. J Transl Med 2008 0.75
87 Tenth annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), SIENA, Italy, November 5-7, 2012. Cancer Immunol Immunother 2013 0.75
88 "Cancer Bio-Immunotherapy in Siena": Eleventh Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 17-19, 2013. Cancer Immunol Immunother 2014 0.75
89 Eighth annual meeting of the Italian network for tumor biotherapy (NIBIT), Siena, October 7-9, 2010. Cancer Immunol Immunother 2011 0.75
90 The Italian Network for Tumor Biotherapy (NIBIT). Sharing visions, goals and efforts at European level. Tumori 2008 0.75
91 Ninth annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), Siena, Italy, October 19-22, 2011: New perspectives in the immunotherapy of cancer. Cancer Immunol Immunother 2012 0.75
92 Sixth annual meeting of the Italian network for tumor biotherapy (NIBIT), Siena, 16-18 October 2008. Cancer Immunol Immunother 2009 0.75
93 Seventh annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), Siena, 1-3 October 2009. Cancer Immunol Immunother 2010 0.75